2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab - PubMed
10 hours ago
- #Immunomodulators
- #COVID-19
- #Clinical Guidelines
- The article presents a focused update to the IDSA clinical practice guideline for COVID-19 treatment.
- It provides a new recommendation comparing baricitinib to tocilizumab for hospitalized adults with severe or critical COVID-19, when a decision to use one of these agents has been made.
- The recommendation does not address combinations of multiple immunomodulatory agents.
- The guideline is based on a systematic literature review and uses the GRADE approach to rate evidence certainty and recommendation strength.
- No panelists had direct conflicts of interest related to the specific clinical question addressed.